AstraZeneca PLC is trying to take a leadership role within the biopharmaceutical sector on the issue of reducing greenhouse gas emissions, with a new initiative to convert all of its US facilities to renewable natural gas, i.e., biogas, by 2026, with greater carbon-reduction goals set for 2030 and 2045. The large pharma is partnering with Vanguard Renewables on the effort and said its suppliers and contractors will need to play a role in achieving the longer-term goals.
As part of its Ambition Zero Carbon initiative, AstraZeneca is converting its manufacturing sites, R&D facilities and office buildings in...
